Related Experiment Video
Updated: Jan 6, 2026
07:15
Intranasal Administration of CNS Therapeutics to Awake Mice
Published on: April 8, 2013
61.3K
Dipeptidyl peptidase-4 inhibitor treatment could decrease chronic rhinosinusitis in diabetic patients
S-Y Li1, H-H Chen2,3,4, C-C Lai5
1From the Department of Otorhinolaryngology, Head and Neck Surgery, Changhua Christian Hospital, Nanhsiau Street, Changhua, Taiwan.
QJM : Monthly Journal of the Association of Physicians
|October 5, 2019
Summary
Dipeptidyl peptidase-4 inhibitor (DPP4i) treatment may reduce the risk of chronic rhinosinusitis (CRS) in diabetic patients. This finding suggests a potential benefit of DPP4i for managing CRS in this population.
Area of Science:
- Endocrinology
- Immunology
- Otolaryngology
Background:
- Diabetes mellitus is a complex condition associated with various complications.
- Chronic rhinosinusitis (CRS) is a prevalent inflammatory condition affecting the upper airways.
- The interplay between diabetes and CRS risk warrants further investigation.
Purpose of the Study:
- To investigate the association between dipeptidyl peptidase-4 inhibitor (DPP4i) use and the incidence of chronic rhinosinusitis (CRS) among diabetic patients.
- To evaluate whether DPP4i treatment influences CRS risk in a Taiwanese diabetic population.
Main Methods:
- A population-based, matched cohort study utilizing the Longitudinal Health Insurance Database.
- Statistical analyses included Chi-square and Wilcoxon rank-sum tests for variable associations.
- Kaplan-Meier method with log-rank test assessed CRS risk in DPP4i users versus non-users.
Main Results:
- The study included 6198 diabetic patients.
- DPP4i users exhibited a significantly lower risk of developing CRS.
- Reduced CRS risk was observed in women, patients with higher Diabetes Complications Severity Index scores, those with comorbidities, and with higher cumulative DPP4i dosage.
Conclusions:
- DPP4 inhibitor treatment is associated with a decreased risk of chronic rhinosinusitis in diabetic patients.
- These findings suggest a potential protective effect of DPP4i against CRS development in this population.
- Further research may explore the mechanisms underlying this observed association.
More Related Videos
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
540
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
540
01:24Glucagon-like Receptor Agonists
809
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
809
01:17Drugs Used in Lower Respiratory Disorders: Overview
995
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
995
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
554
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
554
01:16Insulin: Dosing Regimen and Adverse Effects
644
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
644
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
496
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
496